Recordkeeping fees per participant
not reported
Not reported on this filing.
Employers › Enveda Therapeutics
Enveda Therapeutics 401(k)
- Manufacturing
- Boulder, CO
- EIN 83-4701687
- 1 plan with Schedule H financials
- Plan year 2024
- Enveda Therapeutics, Inc.
Total assets, end of year · Enveda Biosciences 401(k) Plan · plan year 2024
$9,080,971
165 participants with a balance. This filing reports no recordkeeping fee and no administrative expenses excluding investment management, so there is no headline cost figure.
Source
Schedule H, Part I line 1f col (b); TOT_ASSETS_EOY_AMT pos 61; filing 20250709153631NAL0004934641001, received 2025-07-09
participants_with_balance: Form 5500, line 6g(2); PARTCP_ACCOUNT_BAL_CNT pos 78; filing 20250709153631NAL0004934641001, received 2025-07-09
Percentiles compare this plan with the Schedule H plans $1 to 10M in assets of the same plan year, excluding final filings; shown only where at least 50 comparable plans report the figure. Plan year 2024-01-01 to 2024-12-31, filing received 2025-07-09.
Cost and contributions
Administrative expenses excluding investment management, per participant
$0.00
Fewer than 50 comparable plans report this figure; no percentile.
Source
= $0 / 165
derived, admin_expenses (2i(12)) minus invst_mgmt_fees (2i(5)), floored at 0; filing 20250709153631NAL0004934641001, received 2025-07-09
participants_with_balance: Form 5500, line 6g(2); PARTCP_ACCOUNT_BAL_CNT pos 78; filing 20250709153631NAL0004934641001, received 2025-07-09
Administrative expenses per participant
$220.58
Higher than 67% of the 15,210 plans $1 to 10M that report it.
Source
= $36,396 / 165
Schedule H, line 2i(12) total administrative expenses; TOT_ADMIN_EXPENSES_AMT pos 109; filing 20250709153631NAL0004934641001, received 2025-07-09
participants_with_balance: Form 5500, line 6g(2); PARTCP_ACCOUNT_BAL_CNT pos 78; filing 20250709153631NAL0004934641001, received 2025-07-09
Administrative expenses as a share of assets
0.401%
Higher than 39% of the 15,243 plans $1 to 10M that report it.
Source
= $36,396 / $9,080,971
Schedule H, line 2i(12) total administrative expenses; TOT_ADMIN_EXPENSES_AMT pos 109; filing 20250709153631NAL0004934641001, received 2025-07-09
assets_eoy: Schedule H, Part I line 1f col (b); TOT_ASSETS_EOY_AMT pos 61; filing 20250709153631NAL0004934641001, received 2025-07-09
Employer contributions per participant
$5,154
Higher than 99% of the 13,342 plans $1 to 10M that report it.
Source
= $850,473 / 165
Schedule H, Part II line 2a(1)(A); EMPLR_CONTRIB_INCOME_AMT pos 68; filing 20250709153631NAL0004934641001, received 2025-07-09
participants_with_balance: Form 5500, line 6g(2); PARTCP_ACCOUNT_BAL_CNT pos 78; filing 20250709153631NAL0004934641001, received 2025-07-09
Employer share of total contributions
28.8%
Higher than 49% of the 13,370 plans $1 to 10M that report it.
Source
= $850,473 / $2,955,242
Schedule H, Part II line 2a(1)(A); EMPLR_CONTRIB_INCOME_AMT pos 68; filing 20250709153631NAL0004934641001, received 2025-07-09
total_contrib: Schedule H, line 2a(3); TOT_CONTRIB_AMT pos 72; filing 20250709153631NAL0004934641001, received 2025-07-09
Plan terms, as stated in Enveda Therapeutics, Inc.'s SEC filings
Plan terms are not published in public filings.
Plan features
2E profit-sharing · 2F ERISA 404(c) plan · 2G fully participant-directed · 2J 401(k) feature · 2K 401(m) arrangement · 2S pre-approved plan document · 2T default investment (QDIA) · 3D IRS pre-approved plan · Form 5500, line 8a; TYPE_PENSION_BNFT_CODE pos 81; filing 20250709153631NAL0004934641001, received 2025-07-09
Full record, Enveda Biosciences 401(k) Plan
| Field | Value | Source |
|---|---|---|
| Plan sponsor | ENVEDA THERAPEUTICS, INC. | Form 5500, Part II line 2a; SPONSOR_DFE_NAME pos 19; filing 20250709153631NAL0004934641001, received 2025-07-09 |
| Plan name | ENVEDA BIOSCIENCES 401(K) PLAN | Form 5500, line 1a; PLAN_NAME pos 16; filing 20250709153631NAL0004934641001, received 2025-07-09 |
| Sponsor EIN / plan number | 83-4701687 / 001 | Form 5500, line 2b; SPONS_DFE_EIN pos 44; filing 20250709153631NAL0004934641001, received 2025-07-09 |
| Plan type | single-employer | Form 5500, Part I line A; TYPE_PLAN_ENTITY_CD pos 4; filing 20250709153631NAL0004934641001, received 2025-07-09 |
| Sponsor location | BOULDER, CO | Form 5500, line 2a; SPONS_DFE_MAIL_US_STATE pos 25; filing 20250709153631NAL0004934641001, received 2025-07-09 |
| Industry (business code) | 325410, Manufacturing | Form 5500, line 2d; BUSINESS_CODE pos 46; filing 20250709153631NAL0004934641001, received 2025-07-09 |
| Plan year | 2024-01-01 to 2024-12-31 | Form 5500, Part I plan year; FORM_PLAN_YEAR_BEGIN_DATE pos 2; filing 20250709153631NAL0004934641001, received 2025-07-09 |
| Filing received | 2025-07-09 | Form 5500, EFAST2 receipt date; DATE_RECEIVED pos 102; filing 20250709153631NAL0004934641001, received 2025-07-09 |
| Final filing | no | Form 5500, Part I line B; FINAL_FILING_IND pos 8; filing 20250709153631NAL0004934641001, received 2025-07-09 |
| Amended filing | no | Form 5500, Part I line B; AMENDED_IND pos 7; filing 20250709153631NAL0004934641001, received 2025-07-09 |
| Participants, beginning of year | 148 | Form 5500, line 5; TOT_PARTCP_BOY_CNT pos 71; filing 20250709153631NAL0004934641001, received 2025-07-09 |
| Active participants | 129 | Form 5500, line 6a(2); TOT_ACTIVE_PARTCP_CNT pos 72; filing 20250709153631NAL0004934641001, received 2025-07-09 |
| Participants, end of year | 170 | Form 5500, line 6f; TOT_ACT_RTD_SEP_BENEF_CNT pos 77; filing 20250709153631NAL0004934641001, received 2025-07-09 |
| Participants with an account balance | 165 | Form 5500, line 6g(2); PARTCP_ACCOUNT_BAL_CNT pos 78; filing 20250709153631NAL0004934641001, received 2025-07-09 |
| Total assets, beginning of year | $5,805,834 | Schedule H, Part I line 1f col (a); TOT_ASSETS_BOY_AMT pos 30; filing 20250709153631NAL0004934641001, received 2025-07-09 |
| Total assets, end of year | $9,080,971 | Schedule H, Part I line 1f col (b); TOT_ASSETS_EOY_AMT pos 61; filing 20250709153631NAL0004934641001, received 2025-07-09 |
| Net assets, end of year | $9,080,971 | Schedule H, line 1l col (b); NET_ASSETS_EOY_AMT pos 67; filing 20250709153631NAL0004934641001, received 2025-07-09 |
| Total income | $3,882,931 | Schedule H, Part II line 2d; TOT_INCOME_AMT pos 97; filing 20250709153631NAL0004934641001, received 2025-07-09 |
| Net income | $3,275,137 | Schedule H, line 2k; NET_INCOME_AMT pos 111; filing 20250709153631NAL0004934641001, received 2025-07-09 |
| Employer contributions | $850,473 | Schedule H, Part II line 2a(1)(A); EMPLR_CONTRIB_INCOME_AMT pos 68; filing 20250709153631NAL0004934641001, received 2025-07-09 |
| Participant contributions | $1,853,305 | Schedule H, line 2a(1)(B); PARTICIPANT_CONTRIB_AMT pos 69; filing 20250709153631NAL0004934641001, received 2025-07-09 |
| Other contributions (incl. rollovers) | $251,464 | Schedule H, line 2a(1)(C); OTH_CONTRIB_RCVD_AMT pos 70; filing 20250709153631NAL0004934641001, received 2025-07-09 |
| Total contributions | $2,955,242 | Schedule H, line 2a(3); TOT_CONTRIB_AMT pos 72; filing 20250709153631NAL0004934641001, received 2025-07-09 |
| Benefit payments | $571,398 | Schedule H, line 2e(4); TOT_DISTRIB_BNFT_AMT pos 101; filing 20250709153631NAL0004934641001, received 2025-07-09 |
| Total expenses (incl. benefit payments) | $607,794 | Schedule H, line 2j; TOT_EXPENSES_AMT pos 110; filing 20250709153631NAL0004934641001, received 2025-07-09 |
| Total administrative expenses | $36,396 | Schedule H, line 2i(12) total administrative expenses; TOT_ADMIN_EXPENSES_AMT pos 109; filing 20250709153631NAL0004934641001, received 2025-07-09 |
| Investment advisory and management fees | $36,396 | Schedule H, line 2i(5); INVST_MGMT_FEES_AMT pos 107; filing 20250709153631NAL0004934641001, received 2025-07-09 |
| Administrative expenses excluding investment management | $0 | derived, admin_expenses (2i(12)) minus invst_mgmt_fees (2i(5)), floored at 0; filing 20250709153631NAL0004934641001, received 2025-07-09 |
| Held in mutual funds | $9,001,088 | Schedule H, line 1c(13) col (b); INT_REG_INVST_CO_EOY_AMT pos 55; filing 20250709153631NAL0004934641001, received 2025-07-09 |
| Independent auditor | TORRILLO & ASSOCIATES, LLC | Schedule H, Part III line 3a; ACCOUNTANT_FIRM_NAME pos 116; filing 20250709153631NAL0004934641001, received 2025-07-09 |
Position = column in the DOL layout for form year 2024. Filing 20250709153631NAL0004934641001, received 2025-07-09.
Service providers paid directly by the plan
| Provider | Relationship | Service codes | Direct compensation | Indirect |
|---|---|---|---|---|
| HUMAN INTEREST ADVISOR LLCrecordkeeper | RECORDKEEPER | 13 Contract administrator; 27 Investment advisory (plan); 51 Investment management fees paid directly by plan; 15 Recordkeeping and information management | $36,396 | no |
Schedule C Part I line 2: name (a), service codes (b), relationship (c), direct compensation paid by the plan (d), indirect compensation received (e). Filing 20250709153631NAL0004934641001, received 2025-07-09.
What changed since the 2023 plan year
| Figure | 2023 | 2024 | Change |
|---|---|---|---|
| Total assets | $5,805,834 | $9,080,971 | 56.4% |
| Participants with a balance | 138 | 165 | 19.6% |
| Administrative expenses | $20,729 | $36,396 | 75.6% |
| Recordkeeping fees per participant | not reported | not reported | |
| Employer contributions | $601,185 | $850,473 | 41.5% |
Prior filing 20240722124125NAL0021618370001, received 2024-07-22; the plan years are contiguous.
Alerts, claims and corrections
Sponsor name as filed: ENVEDA THERAPEUTICS, INC.; SEC registrant: Enveda Therapeutics, Inc. (CIK 1821392, matched by EIN).